Literature DB >> 26893712

Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells.

Lixia Lv1, Xiumei An2, Hongyan Li1, Lanxiu Ma1.   

Abstract

Doxorubicin has been widely used in the treatment of cancer. However, acquired doxorubicin resistance severely hinders the application of the drug. In the present study, doxorubicin resistance was investigated in lung carcinoma. microRNA-155 (miR-155) was found to be upregulated in the doxorubicin-resistant A549/dox cell line. Suppression of miR-155 in this cell line considerably reversed doxorubicin resistance, and doxorubicin-induced apoptosis and cell cycle arrest were recovered. Furthermore, reverse transcription-polymerase chain reaction and western blot analysis revealed that miR-155 suppression downregulated the expression of multidrug resistance protein 1, multidrug resistance-associated protein 1, breast cancer resistance protein, glutathione S-transferase-π, Survivin and B-cell lymphoma 2, and upregulated the expression of caspase-3 and caspase-8. In addition, it was found that miR-155 suppression inhibited the activation of AKT and extracellular signal-regulated kinase. The transcriptional activity of nuclear factor-κB and activator protein-1 was also downregulated. In summary, the present results indicate that miR-155 may participate in doxorubicin resistance in lung carcinoma. The current study provides a novel target for lung carcinoma treatment.

Entities:  

Keywords:  human lung cancer; microRNA-155; resistance reversal

Year:  2015        PMID: 26893712      PMCID: PMC4734087          DOI: 10.3892/ol.2015.3995

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  43 in total

1.  Dual effects of miR-155 on macrophages at different stages of atherosclerosis: LDL is the key?

Authors:  Erli Zhang; Yongjian Wu
Journal:  Med Hypotheses       Date:  2014-04-13       Impact factor: 1.538

Review 2.  The p53 network.

Authors:  M L Agarwal; W R Taylor; M V Chernov; O B Chernova; G R Stark
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

3.  Role of MiR-3619-5p in β-Catenin-Mediated Non-Small Cell Lung Cancer Growth and Invasion.

Authors:  Xuecai Niu; Sen Liu; Li Jia; Jing Chen
Journal:  Cell Physiol Biochem       Date:  2015-10-30

4.  Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.

Authors:  Pierluigi Gasparini; Francesca Lovat; Matteo Fassan; Lucia Casadei; Luciano Cascione; Naduparambil K Jacob; Stefania Carasi; Dario Palmieri; Stefan Costinean; Charles L Shapiro; Kay Huebner; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-10       Impact factor: 11.205

Review 5.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 6.  Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.

Authors:  Dietrich Keppler
Journal:  Handb Exp Pharmacol       Date:  2011

7.  miR-155* mediates suppressive effect of PTEN 3'-untranslated region on AP-1/NF-κB pathway in HTR-8/SVneo cells.

Authors:  P Xue; M Zheng; Z Diao; L Shen; M Liu; P Gong; H Sun; Y Hu
Journal:  Placenta       Date:  2013-05-16       Impact factor: 3.481

Review 8.  Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review).

Authors:  I Müller; D Niethammer; G Bruchelt
Journal:  Int J Mol Med       Date:  1998-02       Impact factor: 4.101

9.  Correlation between expression of miR-155 in colon cancer and serum carcinoembryonic antigen level and its contribution to recurrence and metastasis forecast.

Authors:  Cao Hongliang; Huang Shaojun; Liu Aihua; Jiang Hua
Journal:  Saudi Med J       Date:  2014-06       Impact factor: 1.484

10.  MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2.

Authors:  Yuan Yuan; Yu Feng Yao; Sai Nan Hu; Jin Gao; Li-Li Zhang
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

View more
  14 in total

1.  MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.

Authors:  Hanne Due; Anna Amanda Schönherz; Laura Ryø; Maria Nascimento Primo; Ditte Starberg Jespersen; Emil Aagaard Thomsen; Anne Stidholt Roug; Min Xiao; Xiaohong Tan; Yuyang Pang; Ken H Young; Martin Bøgsted; Jacob Giehm Mikkelsen; Karen Dybkær
Journal:  Blood Adv       Date:  2019-04-09

Review 2.  Clinical significance of blood-based miRNAs as biomarkers of non-small cell lung cancer.

Authors:  Lin Li; Yu Sun; Min Feng; Liang Wang; Jing Liu
Journal:  Oncol Lett       Date:  2018-04-12       Impact factor: 2.967

3.  Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Authors:  Katrien Van Roosbroeck; Francesca Fanini; Tetsuro Setoyama; Cristina Ivan; Cristian Rodriguez-Aguayo; Enrique Fuentes-Mattei; Lianchun Xiao; Ivan Vannini; Roxana S Redis; Lucilla D'Abundo; Xinna Zhang; Milena S Nicoloso; Simona Rossi; Vianey Gonzalez-Villasana; Rajesha Rupaimoole; Manuela Ferracin; Fortunato Morabito; Antonino Neri; Peter P Ruvolo; Vivian R Ruvolo; Chad V Pecot; Dino Amadori; Lynne Abruzzo; Steliana Calin; Xuemei Wang; M James You; Alessandra Ferrajoli; Robert Orlowski; William Plunkett; Tara M Lichtenberg; Ramana V Davuluri; Ioana Berindan-Neagoe; Massimo Negrini; Ignacio I Wistuba; Hagop M Kantarjian; Anil K Sood; Gabriel Lopez-Berestein; Michael J Keating; Muller Fabbri; George A Calin
Journal:  Clin Cancer Res       Date:  2016-11-30       Impact factor: 12.531

4.  miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1.

Authors:  Guinv Hu; Xiaokang Zhao; Jiang Wang; Liting Lv; Chaoqun Wang; Liang Feng; Liangqiong Shen; Weili Ren
Journal:  Oncol Lett       Date:  2017-11-23       Impact factor: 2.967

5.  miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells.

Authors:  Shiyan Gu; Yanhao Lai; Hongyu Chen; Yuan Liu; Zunzhen Zhang
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

Review 6.  Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer.

Authors:  Kentaro Inamura
Journal:  Cells       Date:  2017-05-09       Impact factor: 6.600

7.  Apoferritin as an ubiquitous nanocarrier with excellent shelf life.

Authors:  Simona Dostalova; Katerina Vasickova; David Hynek; Sona Krizkova; Lukas Richtera; Marketa Vaculovicova; Tomas Eckschlager; Marie Stiborova; Zbynek Heger; Vojtech Adam
Journal:  Int J Nanomedicine       Date:  2017-03-24

8.  Evaluation of latent membrane protein 1 and microRNA-155 for the prognostic prediction of diffuse large B cell lymphoma.

Authors:  Xue Wu; Fei Wang; Yuan Li; Xiyong Wang; Ping Liu; Haijun Zhang; Zheng Ge; Xiaoping Zhang; Chong Gao; Baoan Chen
Journal:  Oncol Lett       Date:  2018-04-24       Impact factor: 2.967

Review 9.  Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression.

Authors:  Lei Zhang; Xiulan Zheng; Wen Cheng; Xuefei Zhang; Lingling Wang; Haixia Li
Journal:  Cell Death Dis       Date:  2020-07-24       Impact factor: 8.469

10.  MicroRNA-155 increases colon cancer chemoresistance to cisplatin by targeting forkhead box O3.

Authors:  Yuewen Gao; Zhaoyan Liu; Zhaohong Ding; Shicai Hou; Jun Li; Kehua Jiang
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.